Home | About Us | Executive Leadership | Preclinical Research | Clinical Research | Training & Education | News & Events | Support our Research
News and Announcements
SJTRI and Cytograft Tissue Engineering are featured in CNN Health (June 28, 2011)
Click here to read the article.
SJTRI is featured in Medical Device Daily’s March 31, 2011 Issue
Learn more about SJTRI in Medical Device Daily.
SJTRI’s New Phase I Unit is featured in CenterWatch Weekly
Click here to learn more about SJTRI in CenterWatch Weekly.
Georgia Tech and SJTRI Partner to Fund New Seed Grant Program
Click here to learn more about the Seed Grant.
SJTRI Announces Scholarship Opportunities for Atlanta Undergraduates
Click here to learn more about the scholarships.
SJTRI is featured in Medical Device Daily’s February 8, 2010 Issue
Learn more about SJTRI in Medical Device Daily.
Saint Joseph’s Translational Research Institute Was Awarded Two Grants
$60,080 from Juvenile Diabetes Research Foundation International
New Combined Encapsulant with T Cell Repellent to Sustain Islet Transplants
This study is a collaborative effort between Massachusetts General Hospital (Harvard Medical School), Georgia Institute of Technology, and Saint Joseph’s Translational Research Institute. The project aims to research a novel method to utilize T cell repellent as a means of overcoming rejection that combines maintenance of long term islet viability with establishment of immune isolation for the engrafted tissue without the need for immune suppressive drug therapy. $332,958 from the National Institutes of Health – Grand Opportunities
Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia
The treatment of bleeding episodes in patients with Hemophilia A consists of transfusions of Factor VIII (FVIII), the protein whose activity is deficient in these patients. However, an immune response in the form of neutralizing antibodies may complicate the therapy. Through joint efforts with Sepulveda Research Corporation and SJTRI, this project will characterize the antibodies and study the genetic influences of this reaction.
Harvard-Trained, Eli Lilly and Company Researcher Joins Saint Joseph’s Translational Research Institute as Chief Scientific Officer
(June 25, 2009) – Saint Joseph’s Translational Research Institute (SJTRI), the research division of Saint Joseph’s Health System, announced today that Jaipal Singh, Ph.D., will join SJTRI as chief scientific officer. Dr. Singh was most recently with Eli Lilly and Company, where he served as head of vascular therapeutics research and research advisor for the Atherosclerosis-Metabolic drug hunting team. Dr. Singh’s research training includes Harvard University Medical School in Boston. Read More
Saint Joseph’s Translational Research Institute Opens State-Of-The-Art, 32,000-Square-Foot Preclinical Research Facility in the Heart of Atlanta
(May 18, 2009) – Saint Joseph’s Translational Research Institute (SJTRI), the research division of Saint Joseph’s Health System, will open its new, state-of-the-art, 32,000-square-foot preclinical research facility on May 19, providing international industry leaders the ability to tour the facility during the 2009 BIO International Convention: The Global Event for Biotechnology held May 18-21, 2009 in Atlanta.
Calendar of Events
October 1: 5th Annual Preventing Heart Disease: Evolving Concepts and New Therapies (Atlanta, Georgia)